Drug intelligence / Profile preview

AD-105

Development stage: Unknown
Lead developer: Addpharma

Overview

AD-105 is an investigational drug candidate currently in Phase 1 clinical development by Addpharma, a South Korean pharmaceutical company specializing in the development of incrementally modified drugs (IMDs). The candidate is being developed for the treatment of gastrointestinal disorders. As of early 2024, specific details regarding its molecular target, active ingredients, and modality have not been publicly disclosed by the developer, although the company's broader pipeline focuses on improved formulations and combinations of existing therapeutic agents.

Beyond the preview

Go deeper on AD-105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-105.

Explore the full profile